Get to know our clinical trials
Phase II clinical trial to evaluate the efficacy and safety of Pirtobrutinib in participants with leukemia who have previously received treatment with a covalent Bruton's tyrosine kinase inhibitor.
CLINICAL TRIAL TO COMPARE THE OVERALL RESPONSE RATE OF: - PIRTOBRUTINIB 200 MG VS. 120 MG - PIRTOBRUTINIB 200 MG VS. 60 MG
Specialist
Hematology and Hemotherapy Department
Madrid headquarters
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE II, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 3 DOSES OF PYRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL CELL LYMPHOCYTIC LYMPHOMA WHO HAVE PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON'S TYROSINE KINASE INHIBITOR.
- Code EudraCT: 2024-515689-15-00
- Protocol number: J2N-MC-JZNX
- Promoter: Lilly
- Molecule/Drug: Pirtobrutinib
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.